ArticleThe International journal on drug policy2022
A mixed methods study of provider factors in buprenorphine treatment retention.
Article in The International journal on drug policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff.Substance abuse treatment, prevention, and policy · 2025Trial
- Implementation Outcomes of Low Threshold Care for Persons with Opioid Use Disorders.Journal of general internal medicine · 2026Article
- Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment.JAMA network open · 2026Article
- Differences in buprenorphine initiation and retention for opioid use disorder between primary care and substance use disorder specialty care settings.Journal of substance use and addiction treatment · 2026Article
- A practice-based implementation strategy bundle for integrating behavioral health in primary care: a matrixed multiple case study.Implementation science communications · 2026Article
- Low-threshold Buprenorphine: Proposing the Ideal Service Model to Engage People With Severe Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Buprenorphine Dispensing Following Medicaid Expansion Amid Unwinding in North Carolina.JAMA network open · 2025Article
- Medicaid Unwinding and Changes in Buprenorphine Dispensing.JAMA network open · 2025Article
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- State-level racial and ethnic disparities in buprenorphine treatment duration in the United States.The American journal on addictions · 2025Article
- Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data.Journal of substance use and addiction treatment · 2025Article
- Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations.Research square · 2024Article
- Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.AIDS and behavior · 2024Article
- Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.Addiction science & clinical practice · 2024Article
- Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.Drug and alcohol dependence · 2024Article
- Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.Addiction science & clinical practice · 2024Observational
- Experiences of Stigma and Discrimination Compounded by Intersecting Identities among Individuals Receiving Medication for Opioid Use Disorder.Journal of health care for the poor and underserved · 2024Article
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices.Addictive behaviors reports · 2023Article
- Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
- Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.JAMA health forum · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLow retention is a persistent challenge in the delivery of buprenorphine treatment for opioid use disorder (OUD). The goal of this study was to identify provider factors that could drive differences in treatment retention while accounting for the contribution of patient characteristics to retention.
methodsWe developed a novel a mixed-methods approach to explore provider factors that could drive retention while accounting for patient characteristics. We used Medicaid claims data from North Carolina in the United States to identify patient characteristics associated with higher retention. We then identified providers who achieved high and low retention rates. We matched high- and low-retention providers on their patients' characteristics. This matching created high- and low-retention provider groups whose patients had similar characteristics. We then interviewed providers while blinded to which belonged in the high- and low-retention groups on aspects of their practice that could affect retention rates, such as treatment criteria, treatment cost, and services offered.
resultsLess than half of patients achieved 180-day treatment retention with large differences by race and ethnicity. We did not find evidence that providers who achieved higher retention consistently did so by providing more comprehensive services or selecting for more stable patients. Rather, our findings suggest use of "high-threshold" clinical approaches, such as requiring participation in psychosocial services or strictly limiting dosages, explain differences in retention rates between providers whose patients have similar characteristics. All low-retention providers interviewed used a high-threshold practice compared to half of high-retention providers interviewed. Requiring patients to participate in psychosocial services, which were often paid out-of-pocket, appeared to be especially important in limiting retention.
conclusionProviders who adopt low-threshold approaches to treatment may achiever higher retention rates than those who adopt high-threshold approaches. Addressing cost barriers and systemic racism are likely also necessary for improving buprenorphine treatment retention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.